Overview

STATEMENT OF NEED

Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with metastatic disease, which is associated with a 5-year survival rate of only 14%.

TARGET AUDIENCE

Medical oncologists, gastroenterologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with CRC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Distinguish prognostic factors that can help tailor treatment to individual patients with metastatic CRC
• Evaluate recent study findings on novel therapies for newly diagnosed and relapsed/refractory metastatic CRC
• Assess strategies to optimize treatment experiences and ensure patient-centered metastatic CRC care

FACULTY

Tanios S. Bekaii-Saab, MD (Chairperson)
Professor of Medicine
Mayo Clinic Cancer Center

Andrea Cercek, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center

John Strickler, MD
Associate Professor of Medicine
Duke University Medical Center

Kristen K. Ciombor, MD, MSCI
Assistant Professor of Medicine
Vanderbilt-Ingram Cancer Center

REGISTRATION

There is no fee to participate in or claim CME credit for this activity.

Provided by

Physicians

i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Tanios S. Bekaii-Saab, MD, discloses that he has served as a consultant for Array Biopharma, Bayer, Boehringer Ingelheim, Daichii Sankyo, Eisai, Genentech, Incyte, Ipsen, Janssen, Merck, Natera, Seagen, Sobi, and TreosBio. He has served on the scientific advisory board for Immuneering, Imugene, and Sun Biopharma. Dr. Bekaii-Saab has also served on the data monitoring committee for 1Globe, AstraZeneca, Exelixis, Lilly, and PanCan. He has received research support from Abgenomics, Amgen, Array Biopharma, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Genentech, Incyte, Ipsen, Lilly, Merck, and Seagen.
​​
Andrea Cercek, MD, discloses that she has served on an advisory board/panel for Array BioPharma and Bayer and that she has received grants/research support from GlaxoSmithKline/Tesaro, Rgenix, and Seagen.

Kristen K. Ciombor, MD, MSCI, discloses that she has served on an advisory board/panel for Array/Pfizer and Natera and that she has received grants/research support from Array/Pfizer, Bristol Myers Squibb, Daiichi Sankyo, Incyte, and NuCana.

John Strickler, MD, discloses that he has served on an advisory board/panel for Amgen, Bayer, Natera, OncoMed, and Seagen and that he has served as a consultant for Amgen, Bayer, and Seagen. Dr. Strickler has also received grants/research support from AbbVie, Amgen, AstraZeneca, Curegenix, Exelixis, Nektar, Roche, Sanofi, and Seagen.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Amgen.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it.